Menu
The AxS platform is poised to solve the biggest challenge in the field of brain therapeutics, by enabling the delivery of biologics across the blood brain barrier in a simple and traceable manner. It pioneers a therapeutic approach, converging the biological process of receptor-mediated transcytosis (RMT) with bioengineered gold nanoparticles (GNPs). The AxS platform’s capabilities can be rapidly adjusted for the creation of multiple therapeutics across many brain diseases. AxS brain-targeted delivery can be quantified and traced, in a clinical setting, in real time, verifying that the therapeutic reaches the brain.
During over a decade of research at Prof. Popovtzer’s Nanoparticles lab, the AxS technology platform was developed and perfected into an efficient gold nanoparticle-based system that can overcome the restrictive mechanism of the BBB. The platform was extensively studied in healthy animals as well as in neurodegenerative disease models and brain tumors.
Using in-vivo CT imaging, AxS platform delivery enables the assessment of delivery of the bioengineered GNPs to specific brain regions that are involved in neurodegenerative and neuropsychiatric disorders.
Nanocarry’s AxS platform can be used to develop a wide array of brain therapeutics, such as antibodies, peptides and other biologics and small molecules with low brain bioavailability. Its unique advantages stem from its convergence of biology and nanotechnology, and include:
One-core technology allows for multiple product generation and a replicable manufacturing process
20-fold in healthy brain,
~40-fold in disease models
Enhanced drug stability and less off-target due to particle retention within the bloodstream
Generate multi-specific particles enabling new mechanisms of action
Targeting capabilities on the cell surface, organelles, or extracellular matrix
GNPs can be traced noninvasively using CT imaging & quantified ex vivo by atomic absorption methods
designed by Studio7Design